The effect of naproxen on acute mountain sickness and vascular responses to hypoxia

R. T. Meehan, A. Cymerman, P. Rock, C. S. Fulco, J. Hoffman, C. Abernathy, S. Needleman, J. T. Maher

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The role of prostaglandins in the pathogenesis of acute mountain sickness and two hypoxia-induced vascular responses was evaluated using the cyclooxygenase inhibitor naproxen. Eleven men spent 24 hours at sea level, followed by 34 hours of decompression to 428 mm Hg while receiving naproxen (N), 250 mg twice daily or placebo (P) in a double-blind crossover trial. Serum naproxen levels measured by high pressure liquid chromatography were changed by hypoxia. The severity of acute mountain sickness (AMS) by the Environmental Symptom Questionnaire scores and observer assessment were unaffected by drug treatment. Retinal artery diameter measured from projected fundus photographs was increased after 27 hours at altitude (11.4 ± .5 mm) vs. sea level (9.4 ± .5 mm, p < 0.05) during both trials. Upright mean arterial pressure fell after 6 hours at altitude (79 ± 3 mm Hg during N and P vs. 92 ± 3 at sea level, p < 0.01). Minute ventilation, end expiratory alveolar PO2 and PCO2 did not differ between drug trials. This study suggests vasodilating prostaglandins do not have a major role in the genesis of AMS, hypoxia-induced retinal vasodilatation, or postural blood pressure responses in man.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalAmerican Journal of the Medical Sciences
Volume292
Issue number1
DOIs
StatePublished - 1 Jan 1986

Fingerprint

Altitude Sickness
Naproxen
Oceans and Seas
Blood Vessels
Prostaglandins
Retinal Artery
Cyclooxygenase Inhibitors
Decompression
Vasodilation
Pharmaceutical Preparations
Cross-Over Studies
Ventilation
Arterial Pressure
High Pressure Liquid Chromatography
Placebos
Blood Pressure
Serum
Hypoxia
Therapeutics

Cite this

Meehan, R. T. ; Cymerman, A. ; Rock, P. ; Fulco, C. S. ; Hoffman, J. ; Abernathy, C. ; Needleman, S. ; Maher, J. T. / The effect of naproxen on acute mountain sickness and vascular responses to hypoxia. In: American Journal of the Medical Sciences. 1986 ; Vol. 292, No. 1. pp. 15-20.
@article{a2e5af2480d74b178b088ab66170fb19,
title = "The effect of naproxen on acute mountain sickness and vascular responses to hypoxia",
abstract = "The role of prostaglandins in the pathogenesis of acute mountain sickness and two hypoxia-induced vascular responses was evaluated using the cyclooxygenase inhibitor naproxen. Eleven men spent 24 hours at sea level, followed by 34 hours of decompression to 428 mm Hg while receiving naproxen (N), 250 mg twice daily or placebo (P) in a double-blind crossover trial. Serum naproxen levels measured by high pressure liquid chromatography were changed by hypoxia. The severity of acute mountain sickness (AMS) by the Environmental Symptom Questionnaire scores and observer assessment were unaffected by drug treatment. Retinal artery diameter measured from projected fundus photographs was increased after 27 hours at altitude (11.4 ± .5 mm) vs. sea level (9.4 ± .5 mm, p < 0.05) during both trials. Upright mean arterial pressure fell after 6 hours at altitude (79 ± 3 mm Hg during N and P vs. 92 ± 3 at sea level, p < 0.01). Minute ventilation, end expiratory alveolar PO2 and PCO2 did not differ between drug trials. This study suggests vasodilating prostaglandins do not have a major role in the genesis of AMS, hypoxia-induced retinal vasodilatation, or postural blood pressure responses in man.",
author = "Meehan, {R. T.} and A. Cymerman and P. Rock and Fulco, {C. S.} and J. Hoffman and C. Abernathy and S. Needleman and Maher, {J. T.}",
year = "1986",
month = "1",
day = "1",
doi = "10.1097/00000441-198607000-00003",
language = "English",
volume = "292",
pages = "15--20",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "1",

}

Meehan, RT, Cymerman, A, Rock, P, Fulco, CS, Hoffman, J, Abernathy, C, Needleman, S & Maher, JT 1986, 'The effect of naproxen on acute mountain sickness and vascular responses to hypoxia', American Journal of the Medical Sciences, vol. 292, no. 1, pp. 15-20. https://doi.org/10.1097/00000441-198607000-00003

The effect of naproxen on acute mountain sickness and vascular responses to hypoxia. / Meehan, R. T.; Cymerman, A.; Rock, P.; Fulco, C. S.; Hoffman, J.; Abernathy, C.; Needleman, S.; Maher, J. T.

In: American Journal of the Medical Sciences, Vol. 292, No. 1, 01.01.1986, p. 15-20.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of naproxen on acute mountain sickness and vascular responses to hypoxia

AU - Meehan, R. T.

AU - Cymerman, A.

AU - Rock, P.

AU - Fulco, C. S.

AU - Hoffman, J.

AU - Abernathy, C.

AU - Needleman, S.

AU - Maher, J. T.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - The role of prostaglandins in the pathogenesis of acute mountain sickness and two hypoxia-induced vascular responses was evaluated using the cyclooxygenase inhibitor naproxen. Eleven men spent 24 hours at sea level, followed by 34 hours of decompression to 428 mm Hg while receiving naproxen (N), 250 mg twice daily or placebo (P) in a double-blind crossover trial. Serum naproxen levels measured by high pressure liquid chromatography were changed by hypoxia. The severity of acute mountain sickness (AMS) by the Environmental Symptom Questionnaire scores and observer assessment were unaffected by drug treatment. Retinal artery diameter measured from projected fundus photographs was increased after 27 hours at altitude (11.4 ± .5 mm) vs. sea level (9.4 ± .5 mm, p < 0.05) during both trials. Upright mean arterial pressure fell after 6 hours at altitude (79 ± 3 mm Hg during N and P vs. 92 ± 3 at sea level, p < 0.01). Minute ventilation, end expiratory alveolar PO2 and PCO2 did not differ between drug trials. This study suggests vasodilating prostaglandins do not have a major role in the genesis of AMS, hypoxia-induced retinal vasodilatation, or postural blood pressure responses in man.

AB - The role of prostaglandins in the pathogenesis of acute mountain sickness and two hypoxia-induced vascular responses was evaluated using the cyclooxygenase inhibitor naproxen. Eleven men spent 24 hours at sea level, followed by 34 hours of decompression to 428 mm Hg while receiving naproxen (N), 250 mg twice daily or placebo (P) in a double-blind crossover trial. Serum naproxen levels measured by high pressure liquid chromatography were changed by hypoxia. The severity of acute mountain sickness (AMS) by the Environmental Symptom Questionnaire scores and observer assessment were unaffected by drug treatment. Retinal artery diameter measured from projected fundus photographs was increased after 27 hours at altitude (11.4 ± .5 mm) vs. sea level (9.4 ± .5 mm, p < 0.05) during both trials. Upright mean arterial pressure fell after 6 hours at altitude (79 ± 3 mm Hg during N and P vs. 92 ± 3 at sea level, p < 0.01). Minute ventilation, end expiratory alveolar PO2 and PCO2 did not differ between drug trials. This study suggests vasodilating prostaglandins do not have a major role in the genesis of AMS, hypoxia-induced retinal vasodilatation, or postural blood pressure responses in man.

UR - http://www.scopus.com/inward/record.url?scp=0022916679&partnerID=8YFLogxK

U2 - 10.1097/00000441-198607000-00003

DO - 10.1097/00000441-198607000-00003

M3 - Article

C2 - 3521277

AN - SCOPUS:0022916679

VL - 292

SP - 15

EP - 20

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 1

ER -